JP Morgan Chase
EBS icon

JP Morgan Chase’s Emergent Biosolutions EBS Stock Holding History

JP Morgan Chase’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,500
Closed -$800K – 5825
2018
Q4 		$800K Buy
+13,500
New +$870K ﹤0.01% 3878

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase's EBS Position: Q1 2026 in Review

JP Morgan Chase increased its Emergent Biosolutions (EBS) stake by 0.88% in Q1 2026, buying an estimated $1.94K and bringing the position to 21,541 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #5544.

JP Morgan Chase first reported a position in EBS in Q2 2013 and has held it in 51 quarters since. The position peaked at $19.9M in Q3 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • JP Morgan Chase held 21,541 shares of Emergent Biosolutions worth $173K as of Q1 2026.
  • JP Morgan Chase bought 187 Emergent Biosolutions shares in Q1 2026, an estimated $1.94K.
  • Emergent Biosolutions made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5544 holding.
  • JP Morgan Chase first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's Emergent Biosolutions position peaked at $19.9M in Q3 2020.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.